Paclitaxel-eluting stents

John Cosgrave, Corbett Simon, Rade Babic, Antonio Colombo

Research output: Contribution to journalArticle

Abstract

Percutaneous coronary intervention and stent implantation is rapidly becoming the most commonly used form of revascularization. The long term results of this procedure are limited by restenosis which is a phenomenon predominantly caused by proliferation of smooth muscle cells. Many devices and pharmaceutical agents have been unsuccessful in preventing this problem. Paclitaxel is an antiproliferative drug that has been extensively studied for the prevention of restenosis. This article will review the trial results of the currently available stent platforms and discuss some of the ongoing studies and future directions for the development of new paclitaxel-eluting stents.

Original languageEnglish
Pages (from-to)229-239
Number of pages11
JournalFuture Cardiology
Volume2
Issue number2
DOIs
Publication statusPublished - Feb 2006

Fingerprint

Paclitaxel
Stents
Percutaneous Coronary Intervention
Pharmaceutical Preparations
Smooth Muscle Myocytes
Equipment and Supplies

Keywords

  • Major adverse cardiac events
  • Paclitaxel-eluting stent
  • Restenosis
  • Revascularization

ASJC Scopus subject areas

  • Molecular Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Cosgrave, J., Simon, C., Babic, R., & Colombo, A. (2006). Paclitaxel-eluting stents. Future Cardiology, 2(2), 229-239. https://doi.org/10.2217/14796678.2.2.229

Paclitaxel-eluting stents. / Cosgrave, John; Simon, Corbett; Babic, Rade; Colombo, Antonio.

In: Future Cardiology, Vol. 2, No. 2, 02.2006, p. 229-239.

Research output: Contribution to journalArticle

Cosgrave, J, Simon, C, Babic, R & Colombo, A 2006, 'Paclitaxel-eluting stents', Future Cardiology, vol. 2, no. 2, pp. 229-239. https://doi.org/10.2217/14796678.2.2.229
Cosgrave J, Simon C, Babic R, Colombo A. Paclitaxel-eluting stents. Future Cardiology. 2006 Feb;2(2):229-239. https://doi.org/10.2217/14796678.2.2.229
Cosgrave, John ; Simon, Corbett ; Babic, Rade ; Colombo, Antonio. / Paclitaxel-eluting stents. In: Future Cardiology. 2006 ; Vol. 2, No. 2. pp. 229-239.
@article{62a92a5b8ba54cd5b6fe9581c6a01a23,
title = "Paclitaxel-eluting stents",
abstract = "Percutaneous coronary intervention and stent implantation is rapidly becoming the most commonly used form of revascularization. The long term results of this procedure are limited by restenosis which is a phenomenon predominantly caused by proliferation of smooth muscle cells. Many devices and pharmaceutical agents have been unsuccessful in preventing this problem. Paclitaxel is an antiproliferative drug that has been extensively studied for the prevention of restenosis. This article will review the trial results of the currently available stent platforms and discuss some of the ongoing studies and future directions for the development of new paclitaxel-eluting stents.",
keywords = "Major adverse cardiac events, Paclitaxel-eluting stent, Restenosis, Revascularization",
author = "John Cosgrave and Corbett Simon and Rade Babic and Antonio Colombo",
year = "2006",
month = "2",
doi = "10.2217/14796678.2.2.229",
language = "English",
volume = "2",
pages = "229--239",
journal = "Future Cardiology",
issn = "1479-6678",
publisher = "Future Medicine Ltd.",
number = "2",

}

TY - JOUR

T1 - Paclitaxel-eluting stents

AU - Cosgrave, John

AU - Simon, Corbett

AU - Babic, Rade

AU - Colombo, Antonio

PY - 2006/2

Y1 - 2006/2

N2 - Percutaneous coronary intervention and stent implantation is rapidly becoming the most commonly used form of revascularization. The long term results of this procedure are limited by restenosis which is a phenomenon predominantly caused by proliferation of smooth muscle cells. Many devices and pharmaceutical agents have been unsuccessful in preventing this problem. Paclitaxel is an antiproliferative drug that has been extensively studied for the prevention of restenosis. This article will review the trial results of the currently available stent platforms and discuss some of the ongoing studies and future directions for the development of new paclitaxel-eluting stents.

AB - Percutaneous coronary intervention and stent implantation is rapidly becoming the most commonly used form of revascularization. The long term results of this procedure are limited by restenosis which is a phenomenon predominantly caused by proliferation of smooth muscle cells. Many devices and pharmaceutical agents have been unsuccessful in preventing this problem. Paclitaxel is an antiproliferative drug that has been extensively studied for the prevention of restenosis. This article will review the trial results of the currently available stent platforms and discuss some of the ongoing studies and future directions for the development of new paclitaxel-eluting stents.

KW - Major adverse cardiac events

KW - Paclitaxel-eluting stent

KW - Restenosis

KW - Revascularization

UR - http://www.scopus.com/inward/record.url?scp=33646597258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646597258&partnerID=8YFLogxK

U2 - 10.2217/14796678.2.2.229

DO - 10.2217/14796678.2.2.229

M3 - Article

C2 - 19804079

AN - SCOPUS:33646597258

VL - 2

SP - 229

EP - 239

JO - Future Cardiology

JF - Future Cardiology

SN - 1479-6678

IS - 2

ER -